The state invested heavily to support the development of new drugs or pharmaceutical companies

According to an authoritative source, the state will allocate special funds of several billion yuan to support the research and development of new drugs, and the relevant companies will be short-listed by applying for the topic. According to the requirements, the new drugs to be listed must have broad market development prospects and can solve the most urgent and serious disease prevention and control problems.

Public information revealed that the announcement made by Hengrui Pharmaceuticals on June 15 showed that the company’s new class of drugs, “Aipupu Tablets and Raw Materials”, had been awarded “New Drug Certificate” and “Drug Registration Approval” issued by the State Food and Drug Administration. The drug was the first drug in the country approved by the company to be listed. It was announced that the drug was mainly used to relieve the pain symptoms of osteoarthritis, and the market has good prospects for development. The anti-cancer drug grafted nano-carbon of Lai Mei Pharmaceutical has been Obtained the “Eleventh Five-Year” major new drug creation science and technology major special subject, and obtained the state financial appropriation 1.42 million yuan, this time is more likely to be included in the rolling support topic; Huashen Group semi-annual report disclosed in 2011, its treatment of primary Liver cancer Likatin has entered clinical phase IV, and follow-up will cooperate with scientific research projects and build wards together with local liver cancer treatment key medicines to jointly advance the construction of "Licatin Clinical Research and Development Center" and "Licatin Treatment Center". Due to the lack of effective primary liver cancer medication in China, the market demand for the drug is urgent; the antitumor drug of the Hisun Pharmaceutical Co., Ltd. is doxorubicin, which is an international and domestic market. Sales of anti-cancer drugs, production capacity and market size there is further room for improvement.

Analysts pointed out that the above-mentioned company's various new drugs are in line with the state's key support for new drug research and development projects. If selected, it can obtain national special fund support, but also establish a brand image, which is conducive to the company's follow-up market development.